Amgen Inc. on Thursday said it would lay off about 450 employees, or less than 2% of its workforce, as it faces increasing pressure from drug prices and high inflation.
By Davit Kirakosyan Wells Fargo upgraded Amgen (NASDAQ:AMGN) and Eli Lilly (NYSE:LLY) while downgrading Merck (NYSE:MRK). Amgen was upgraded to Overweight from Equal Weight with a...
Amgen (NASDAQ:AMGN) declared a quarterly dividend of $2.13 per share, or $8.52 annualized. The dividend will be payable on June 8, 2023, to stockholders of record on May 18, 2023,...
U.S. stocks suffered their worst losses since 2008 The market could move higher in 2023 if the Fed slows interest-rate hikes and geopolitical tensions calm down But don’t...
The market jumped on Powell's dovish comments and soft CPI reading in November However, there's been little follow-through on that rally as investors await further clues from the...
Federal Reserve unlikely to pivot Dow has failed to hold breakouts above 200-day in 2022 Index's impressive rally means bears require confirmation Speculation that the Federal...
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
| Average | 254.000 (+6.709% Upside) |
| High | 325.000 |
| Low | 175.000 |
| Price | 238.030 |
| No. of Analysts | 26 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Neutral | Sell | Sell | Buy | Strong Buy |
| Technical Indicators | Buy | Sell | Strong Sell | Strong Buy | Strong Buy |
| Summary | Neutral | Sell | Strong Sell | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 18.14 | 18.21 | 17.63 | -0.13 | -0.71% | 2.91M | Toronto | |||
| 28.41 | 28.50 | 27.98 | -0.15 | -0.53% | 600.91K | Toronto | |||
| 2.07 | 2.11 | 1.97 | -0.0200 | -0.96% | 31.50K | TSXV | |||
| 0.165 | 0.17 | 0.165 | 0.00 | 0.00% | 74.38K | TSXV | |||
| 0.81 | 0.81 | 0.78 | +0.0200 | +2.53% | 235.48K | TSXV | |||
| 0.99 | 1.04 | 0.98 | -0.05 | -4.81% | 7.60K | Toronto | |||
| 71.48 | 71.48 | 70.90 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 1.57 | 1.58 | 1.52 | -0.01 | -0.63% | 116.41K | TSXV | |||
| 0.22 | 0.245 | 0.215 | -0.0250 | -10.20% | 138.36K | TSXV | |||
| 0.03 | 0.03 | 0.03 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 24.98 | 24.98 | 24.98 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 24.13 | 24.17 | 23.63 | +0.13 | +0.54% | 639.05K | Toronto | |||
| 11.00 | 11.00 | 10.61 | +0.37 | +3.48% | 3.32M | Toronto | |||
| 64.81 | 65.59 | 62.50 | +1.250 | +1.97% | 614.03K | Toronto | |||
| 33.00 | 33.09 | 32.98 | -0.15 | -0.45% | 657.00 | Toronto |